Download PDF
Semin Respir Crit Care Med 2022; 43(01): 125-130
DOI: 10.1055/s-0041-1740972
Review Article

Antibiotic Optimization in the Intensive Care Unit

Bryan D. Lizza
1   Barnes Jewish Hospital, Saint Louis, Missouri
,
Nick Raush
1   Barnes Jewish Hospital, Saint Louis, Missouri
2   Forrest General Hospital, Hattiesburg, Mississippi
,
Scott T. Micek
1   Barnes Jewish Hospital, Saint Louis, Missouri
3   University of Health Sciences and Pharmacy, Saint Louis, Missouri
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Effective antimicrobial therapy remains paramount to successful treatment of patients with critical illness, such as pneumonia and sepsis. Unfortunately, critically ill patients often exhibit altered pharmacokinetics and pharmacodynamics (PK/PD) that make this endeavor challenging. Particularly in sepsis, alterations in volume of distribution (Vd) and protein binding lead to unpredictable effects on serum levels of various antimicrobials. Additionally, metabolic pathways and excretion may be significantly impacted due to end-organ failure. These dynamic factors may increase the likelihood of deleterious effects such as treatment failure or toxicity. Meeting these challenging scenarios has led to various strategies meant to improve clinical cure without untoward consequences. Vancomycin and β-lactam antimicrobials are frequently utilized and have been the focus of dose optimization strategies including extended infusion (EI) or continuous infusion (CI). Available data suggests that administration of vancomycin by CI may reduce the risk of nephrotoxicity without increasing the risk of treatment failure, although retrospective data are largely utilized in supporting this method. Other efforts to optimize vancomycin have focused on transitioning from trough-based therapeutic drug monitoring (TDM) to area-under-the-curve: minimum inhibitory concentration (AUC:MIC) ratios. Despite the creation of more user-friendly methods of calculation and data suggesting reduced rates of nephrotoxicity, widespread implementation is limited, in part due to clinician comfort. Use of β-lactams in patients with sepsis is similarly problematic due to observational data demonstrating fluctuations in serum levels in the setting of critical illness. Implementing TDM of agents such as piperacillin-tazobactam, cefepime, and meropenem has been suggested as a method of improving time above MIC (T >MIC). This practice is limited by the lack of access to commercial assays and the failure of rigorous studies to demonstrate improved treatment success. Clinicians should be aware of these challenges and should refine their dosing strategies based on individualized patient factors to reduce treatment failure.

Keywords

pharmacokinetics - area under the curve - extended infusion - therapeutic drug monitoring - critical illness


Publication History

Article published online:
16 February 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Kemmler CB, Sangal RB, Rothenberg C. et al. Delays in antibiotic redosing: Association with inpatient mortality and risk factors for delay. Am J Emerg Med 2021; 46: 63-69
    CrossrefPubMedGoogle Scholar
  • 2 Leisman D, Huang V, Zhou Q. et al. Delayed second dose antibiotics for patients admitted from the emergency department with sepsis: prevalence, risk factors, and outcomes. Crit Care Med 2017; 45 (06) 956-965
    CrossrefPubMedGoogle Scholar
  • 3 Seymour CW, Gesten F, Prescott HC. et al. Time to treatment and mortality during mandated emergency care for sepsis. N Engl J Med 2017; 376 (23) 2235-2244
    CrossrefPubMedGoogle Scholar
  • 4 Seymour CW, Kahn JM, Martin-Gill C. et al. Delays from first medical contact to antibiotic administration for sepsis. Crit Care Med 2017; 45 (05) 759-765
    CrossrefPubMedGoogle Scholar
  • 5 Evans L, Rhodes A, Alhazzani W. et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med 2021; 49 (11) e1063-e1143
    CrossrefPubMedGoogle Scholar
  • 6 Smith BS, Yogaratnam D, Levasseur-Franklin KE, Forni A, Fong J. Introduction to drug pharmacokinetics in the critically ill patient. Chest 2012; 141 (05) 1327-1336
    CrossrefPubMedGoogle Scholar
  • 7 Lelubre C, Vincent JL. Mechanisms and treatment of organ failure in sepsis. Nat Rev Nephrol 2018; 14 (07) 417-427
    CrossrefPubMedGoogle Scholar
  • 8 Bastida C, Hernández-Tejero M, Aziz F. et al. Meropenem population pharmacokinetics in patients with decompensated cirrhosis and severe infections. J Antimicrob Chemother 2020; 75 (12) 3619-3624
    CrossrefPubMedGoogle Scholar
  • 9 Triginer C, Izquierdo I, Fernández R. et al. Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med 1990; 16 (05) 303-306
    CrossrefPubMedGoogle Scholar
  • 10 Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009; 37 (03) 840-851 , quiz 859
    CrossrefPubMedGoogle Scholar
  • 11 Roberts DM, Roberts JA, Roberts MS. et al; RENAL Replacement Therapy Study Investigators. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med 2012; 40 (05) 1523-1528
    CrossrefPubMedGoogle Scholar
  • 12 Wunderink RG, Niederman MS, Kollef MH. et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012; 54 (05) 621-629
    CrossrefPubMedGoogle Scholar
  • 13 Rybak M, Lomaestro B, Rotschafer JC. et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66 (01) 82-98
    CrossrefPubMedGoogle Scholar
  • 14 Rybak MJ, Le J, Lodise TP. et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2020; 71 (06) 1361-1364
    CrossrefPubMedGoogle Scholar
  • 15 Neely MN, Kato L, Youn G. et al. Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing. Antimicrob Agents Chemother 2018; 62 (02) e02042-17
    CrossrefPubMedGoogle Scholar
  • 16 Oda K, Jono H, Nosaka K, Saito H. Reduced nephrotoxicity with vancomycin therapeutic drug monitoring guided by area under the concentration-time curve against a trough 15-20 μg/mL concentration. Int J Antimicrob Agents 2020; 56 (04) 106109
    CrossrefPubMedGoogle Scholar
  • 17 Jorgensen SCJ, Stewart JJ, Dalton B. Vancomycin AUC-guided therapeutic drug monitoring to reduce nephrotoxicity: are we overlooking a simpler solution? Comment on: Oda K, Jono H, Nosaka K, Saito H. Reduced nephrotoxicity in vancomycin therapeutic drug monitoring guided by area under the concentration-time curve against trough 15-20 µg/mL concentration. Int J Antimicrob Agents 2020; 56 (05) 106150
    CrossrefPubMedGoogle Scholar
  • 18 Covvey JR, Erickson O, Fiumara D. et al. Comparison of vancomycin area-under-the-curve dosing versus trough target-based dosing in obese and nonobese patients with methicillin-resistant Staphylococcus aureus bacteremia. Ann Pharmacother 2020; 54 (07) 644-651
    CrossrefPubMedGoogle Scholar
  • 19 Turner RB, Kojiro K, Shephard EA. et al. Review and validation of Bayesian dose-optimizing software and equations for calculation of the vancomycin area under the curve in critically ill patients. Pharmacotherapy 2018; 38 (12) 1174-1183
    CrossrefPubMedGoogle Scholar
  • 20 Meng L, Wong T, Huang S. et al. Conversion from vancomycin trough concentration-guided dosing to area under the curve-guided dosing using two sample measurements in adults: implementation at an Academic Medical Center. Pharmacotherapy 2019; 39 (04) 433-442
    CrossrefPubMedGoogle Scholar
  • 21 Flannery AH, Hammond DA, Oyler DR. et al. Vancomycin dosing practices among critical care pharmacists: a survey of society of critical care medicine pharmacists. Infect Dis (Auckl) 2020; 13: 1178633720952078
    CrossrefPubMedGoogle Scholar
  • 22 Schmelzer TM, Christmas AB, Norton HJ, Heniford BT, Sing RF. Vancomycin intermittent dosing versus continuous infusion for treatment of ventilator-associated pneumonia in trauma patients. Am Surg 2013; 79 (11) 1185-1190
    CrossrefPubMedGoogle Scholar
  • 23 Hong LT, Goolsby TA, Sherman DS. et al. Continuous infusion vs intermittent vancomycin in neurosurgical intensive care unit patients. J Crit Care 2015; 30 (05) 1153.e1-1153.e6
    CrossrefPubMedGoogle Scholar
  • 24 Hutschala D, Kinstner C, Skhirdladze K, Thalhammer F, Müller M, Tschernko E. Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion. Anesthesiology 2009; 111 (02) 356-365
    CrossrefPubMedGoogle Scholar
  • 25 Flannery AH, Bissell BD, Bastin MT, Morris PE, Neyra JA. Continuous versus intermittent infusion of vancomycin and the risk of acute kidney injury in critically ill adults: a systematic review and meta-analysis. Crit Care Med 2020; 48 (06) 912-918
    CrossrefPubMedGoogle Scholar
  • 26 Honore PM, Redant S, De Bels D. Continuous versus intermittent infusion of vancomycin: toward the end of the controversy or even closer to the swan song?. Crit Care Med 2020; 48 (06) 932-933
    CrossrefPubMedGoogle Scholar
  • 27 Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990; 25 (04) 679-687
    CrossrefPubMedGoogle Scholar
  • 28 Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166 (19) 2138-2144
    CrossrefPubMedGoogle Scholar
  • 29 Rostas SE, Kubiak DW, Calderwood MS. High-dose intravenous vancomycin therapy and the risk of nephrotoxicity. Clin Ther 2014; 36 (07) 1098-1101
    CrossrefPubMedGoogle Scholar
  • 30 Mullins BP, Kramer CJ, Bartel BJ, Catlin JS, Gilder RE. Comparison of the nephrotoxicity of vancomycin in combination with cefepime, meropenem, or piperacillin/tazobactam: a prospective, multicenter study. Ann Pharmacother 2018; 52 (07) 639-644
    CrossrefPubMedGoogle Scholar
  • 31 Schreier DJ, Kashani KB, Sakhuja A. et al. Incidence of acute kidney injury among critically ill patients with brief empiric use of antipseudomonal β-lactams with vancomycin. Clin Infect Dis 2019; 68 (09) 1456-1462
    CrossrefPubMedGoogle Scholar
  • 32 Blevins AM, Lashinsky JN, McCammon C, Kollef M, Micek S, Juang P. Incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin-tazobactam, cefepime, or meropenem. Antimicrob Agents Chemother 2019; 63 (05) e02658-18
    CrossrefPubMedGoogle Scholar
  • 33 Hites M, Taccone FS, Wolff F. et al. Case-control study of drug monitoring of β-lactams in obese critically ill patients. Antimicrob Agents Chemother 2013; 57 (02) 708-715
    CrossrefPubMedGoogle Scholar
  • 34 Udy AA, Varghese JM, Altukroni M. et al. Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 2012; 142 (01) 30-39
    CrossrefPubMedGoogle Scholar
  • 35 Jaruratanasirikul S, Sriwiriyajan S, Punyo J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother 2005; 49 (04) 1337-1339
    CrossrefPubMedGoogle Scholar
  • 36 Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 2010; 35 (02) 156-163
    CrossrefPubMedGoogle Scholar
  • 37 Abdul-Aziz MH, Lipman J, Akova M. et al; DALI Study Group. Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the defining antibiotic levels in intensive care unit patients (DALI) cohort. J Antimicrob Chemother 2016; 71 (01) 196-207
    CrossrefPubMedGoogle Scholar
  • 38 Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis 2013; 56 (02) 272-282
    CrossrefPubMedGoogle Scholar
  • 39 Dulhunty JM, Roberts JA, Davis JS. et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis 2013; 56 (02) 236-244
    CrossrefPubMedGoogle Scholar
  • 40 Dulhunty JM, Roberts JA, Davis JS. et al; BLING II Investigators for the ANZICS Clinical Trials Group *. A multicenter randomized trial of continuous versus intermittent β-lactam infusion in severe sepsis. Am J Respir Crit Care Med 2015; 192 (11) 1298-1305
    CrossrefPubMedGoogle Scholar
  • 41 Felton TW, Goodwin J, O'Connor L. et al. Impact of bolus dosing versus continuous infusion of piperacillin and tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa . Antimicrob Agents Chemother 2013; 57 (12) 5811-5819
    CrossrefPubMedGoogle Scholar
  • 42 Wong G, Brinkman A, Benefield RJ. et al. An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units. J Antimicrob Chemother 2014; 69 (05) 1416-1423
    CrossrefPubMedGoogle Scholar
  • 43 Imani S, Alffenaar JW, Cotta MO. et al. Therapeutic drug monitoring of commonly used anti-infective agents: a nationwide cross-sectional survey of Australian hospital practices. Int J Antimicrob Agents 2020; 56 (06) 106180
    CrossrefPubMedGoogle Scholar
  • 44 Imani S, Buscher H, Marriott D, Gentili S, Sandaradura I. Too much of a good thing: a retrospective study of β-lactam concentration-toxicity relationships. J Antimicrob Chemother 2017; 72 (10) 2891-2897
    CrossrefPubMedGoogle Scholar
  • 45 Imani S, Buscher H, Day R. et al. An evaluation of risk factors to predict target concentration non-attainment in critically ill patients prior to empiric β-lactam therapy. Eur J Clin Microbiol Infect Dis 2018; 37 (11) 2171-2175
    CrossrefPubMedGoogle Scholar
  • 46 Sinnollareddy MG, Roberts JA, Lipman J. et al; DALI Study authors. Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: data from multinational defining antibiotic levels in intensive care unit (DALI) patients study. Crit Care 2015; 19: 33
    CrossrefPubMedGoogle Scholar
  • 47 Roberts JA, Paul SK, Akova M. et al; DALI Study. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?. Clin Infect Dis 2014; 58 (08) 1072-1083
    CrossrefPubMedGoogle Scholar
  • 48 Sandaradura I, Alffenaar JW, Cotta MO. et al. Emerging therapeutic drug monitoring of anti-infective agents in Australian hospitals: Availability, performance and barriers to implementation. Br J Clin Pharmacol 2022; 88 (02) 669-679
    CrossrefPubMedGoogle Scholar
  • 49 Economou CJP, Wong G, McWhinney B, Ungerer JPJ, Lipman J, Roberts JA. Impact of β-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents 2017; 49 (05) 589-594
    CrossrefPubMedGoogle Scholar
  • 50 Beumier M, Casu GS, Hites M. et al. β-lactam antibiotic concentrations during continuous renal replacement therapy. Crit Care 2014; 18 (03) R105
    CrossrefPubMedGoogle Scholar
  • 51 Huttner A, Von Dach E, Renzoni A. et al. Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study. Int J Antimicrob Agents 2015; 45 (04) 385-392
    CrossrefPubMedGoogle Scholar
  • 52 Schoenenberger-Arnaiz JA, Ahmad-Diaz F, Miralbes-Torner M, Aragones-Eroles A, Cano-Marron M, Palomar-Martinez M. Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: a prospective cohort study in critically ill patients. Eur J Hosp Pharm Sci Pract 2020; 27 (e1): e30-e35
    CrossrefPubMedGoogle Scholar
  • 53 Abdulla A, Ewoldt TMJ, Hunfeld NGM. et al. The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: the DOLPHIN trial protocol of a multi-centre randomised controlled trial. BMC Infect Dis 2020; 20 (01) 57
    CrossrefPubMedGoogle Scholar